1.Observation of the effect of cefuroxime combined with methylprednisolone in the treatment of chronic obstructive pulmonary disease with emphysema
Yonghua ZHANG ; Shuifang CHEN ; Minzhen ZHANG ; Shiyuan CHEN
Chinese Journal of Primary Medicine and Pharmacy 2017;24(10):1515-1519
Objective To observe and analyze the clinical effect of cefuroxime combined with methylprednisolone in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD) complicated with pulmonary emphysema.Methods 92 COPD patients complicated with pulmonary emphysema were selected as study objects,and they were randomly divided into observation group and control group.46 cases in the control group were treated with antibiotic treatment, and 46 cases in the observation group were treated with cefuroxime combined with methylprednisolone.The clinical curative effect, pulmonary function, blood gas index and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.30%, which was significantly higher than 76.09% of the control group (x2=8.476,P<0.05).The pulmonary function indices including FVC%,FEV1,FEV1%,MVV levels in the observation group were higher than those in the control group (t=2.657,3.610,2.413,2.359,all P<0.05).The PaO2 level in the observation group [(80.3±2.8)mmHg] was higher than (74.1±3.8)mmHg in the control group, the PaCO2 level in the observation group [(34.0±1.1)mmHg] was significantly lower than (40.2±2.2)mmHg in the control group, the differences were statistically significant (t=3.021,3.952,all P<0.05).The incidence rate of adverse reactions of the observation group was 6.52%,which of the control group was 10.87%, the difference was not significant (x2=1.363,P>0.05).Conclusion In elderly COPD patients with emphysema, using cefuroxime combined with methylprednisolone therapy can effectively alleviate the clinical symptoms, improve lung function and blood gas index, and has less adverse reactions, higher safety and high clinical application value.
2.Effect of water deficit on gene expression of enzymes related with hydrogen peroxide detoxification system in Scutellaria baicalensis.
Chong WU ; Shuangshuang QIN ; Yuan YUAN ; Ping CHEN ; Shuifang LIN
China Journal of Chinese Materia Medica 2012;37(2):186-188
OBJECTIVETo analysis the effects of water deficit on the transcript level of SOD, APX, DHAR and MDHAR genes in Scutellaria baicalensis.
METHODThree-month-old S. baicalensis was in glasshouse under water deficit stress, and the transcript level of SOD, APX, DHAR and MDHAR genes were analysis utilized semi-quantitative RT-PCR.
RESULTCompared with the control group, a significant decline of the transcriptional level of APX gene was observed at 70 days after water deficit. The transcript level of DHAR gene was reduced at 30 and 50 days after water deficit. And MDHARI gene was significant declined at 50 days.
CONCLUSIONAsA which is an important antioxidant plays a major role in hydrogen peroxide clear system under water deficit, and maybe have an antagonistic effect to the accumulation of baicalein.
Ascorbate Peroxidases ; genetics ; metabolism ; Ascorbic Acid ; metabolism ; Gene Expression Regulation, Enzymologic ; drug effects ; Gene Expression Regulation, Plant ; drug effects ; Hydrogen Peroxide ; metabolism ; NADH, NADPH Oxidoreductases ; genetics ; metabolism ; Oxidoreductases ; genetics ; metabolism ; Plant Proteins ; genetics ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Scutellaria baicalensis ; enzymology ; genetics ; metabolism ; Superoxide Dismutase ; genetics ; metabolism ; Time Factors ; Water ; metabolism ; pharmacology
3.Clinical application progress of tofacitinib in rheumatoid arthritis
Chinese Journal of Primary Medicine and Pharmacy 2022;29(10):1594-1596
Tofacitinib is a novel targeted drug for the treatment of rheumatoid arthritis. With the entry into the medical insurance catalogue, the drug will usher in a new era. This paper reviews the effectiveness and safety of tofacitinib in the treatment of rheumatoid arthritis. Generally speaking, tofacitinib has definite efficacy, few adverse reactions, and controllable safety. Tofacitinib has an advantage over biological agents, that is, tofacitinib can be orally administered. Therefore, tofacitinib is especially developed for patients who have a poor response to or who are intolerant to disease-modifying antirheumatic drugs and biological agents. However, the effectiveness and safety of tofacitinib in a Chinese population need to be confirmed by more studies.